Myasthenia Gravis clinical trials

The registry lists 330 studies for Myasthenia Gravis across more than 10 countries. 144 are recruiting or about to start. 274 of them are mainly about Myasthenia Gravis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its narrower condition Lambert-Eaton Myasthenic Syndrome too: 345 studies, 145 open.

Get an email when these change. Save the Myasthenia Gravis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 114
Recruiting: 104
Not yet recruiting: 33
Active, not recruiting: 28
Status unknown: 19
Terminated: 16

Phase

Phase 3: 82
Phase 2: 58
Phase 1: 34
Early Phase 1: 13
Phase 4: 10

Where

United States: 144
China: 88
Italy: 67
Canada: 59
Germany: 58
France: 56

Who runs them

argenx (18) · Alexion Pharmaceuticals, Inc. (16) · UCB Biopharma SRL (14) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (6) · Leiden University Medical Center (5) · Charite University, Berlin, Germany (5) · Centre Hospitalier Universitaire de Nice (5) · Tongji Hospital (5)

What is being tested here

Drugs under test in Myasthenia Gravis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Efgartigimod alfa	7	11	16
Telitacicept	4	3	6
Zilucoplan	3	7	8
Nipocalimab	3	3	5
Rozanolixizumab	2	8	10
Ravulizumab	2	3	4
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F	2	0	3
Tocilizumab	2	1	2
Rituximab	1	3	7
Hyaluronidase (human recombinant)	1	4	4

Drug classes tested here Antimetabolites 3

Coming up

38phase 3 studies under way

56studies finish main data collection within a year17 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis · Phase 3 · Alexion Pharmaceuticals, Inc.
Dec 2026Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis · Phase 3 · Cartesian Therapeutics
Dec 2026A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. · Phase 3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
Dec 2026A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) · Phase 3 · RemeGen Co., Ltd.
Jan 2027Efgartigimod in IVIG Dependent Myasthenia Gravis Patients · Phase 3 · Clinique Neuro-Outaouais
Mar 2027Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis · Phase 3 · argenx
Mar 2027A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) · Phase 3 · Vor Biopharma
Apr 2027A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. · Phase 3 · Novartis Pharmaceuticals
May 2027A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis · Phase 3 · UCB Biopharma SRL
Jun 2027EFG vs IVIG in TAMG · Phase 3 · Shanghai Zhongshan Hospital

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger. 16 (15%) take children under 18. 4 (4%) are for women only and 0 (0%) for men only; 13 (13%) take healthy volunteers.

Recruiting studies that take each age, of 104
Age	Women	Men
10	13 (13%)	11 (11%)
18	94 (90%)	91 (88%)
30	98 (94%)	94 (90%)
40	98 (94%)	94 (90%)
50	98 (94%)	94 (90%)
65	96 (92%)	94 (90%)
75	88 (85%)	86 (83%)
85	69 (66%)	67 (64%)

Across all 330 studies, recruiting or not: 23% stop at 75 or younger and 11% at 65; 16% take children; 1% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myasthenia Gravis studies take

Of 52 phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	18 mo13–30 · 22 studies	—	—
Phase 3	30 mo20–43 · 52 studies	27 mo19–39 · 43 studies	—
Interventional, no phase	24 mo11–49 · 35 studies	—	—
Observational	52 mo24–… · 62 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting2

Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360Nov 5, 2026NCT07323316
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisOct 22, 2026NCT07622342

Newly registered1

A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia GravisNov 5, 2026NCT07917923

Studies

Recruiting first, then most recently updated. Showing 50 of 330. Browse all 330 → or search them.